Research Chemical is a recurring topic in our peptide coverage. This hub collects every article tagged Research Chemical, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical monograph on CJC-1293 — an abandoned albumin-binding GHRH analog from the ConjuChem program that produced CJC-1295. No dedicated human data exist; the evidence grade is D, and it is explicitly banned by WADA.
A clinical monograph on Prostamax — the synthetic prostate-tropic tetrapeptide Lys-Glu-Asp-Pro (KEDP) from the Khavinson school. The human prostate evidence belongs to the parent bovine-prostate extract, not the synthetic peptide.
A clinical monograph on Cardiogen (AEDR; H-Ala-Glu-Asp-Arg-OH), the cardiac-targeted Khavinson bioregulator tetrapeptide. Coherent in-vitro mechanism, zero human trials, and an unapproved 2026 legal status.
A clinical monograph on IGF-1 LR3 (Long R3 IGF-1) — the IGFBP-evading, long-acting IGF-1 receptor agonist sold as a lab reagent. Real animal anabolic signal, zero human trials, and serious hypoglycemia and cancer-promotion concerns.
A clinical monograph on des(1-3)IGF-I — the truncated, IGFBP-evading IGF-1 analogue marketed for localized muscle growth. Potent in rodents, unproven in humans, and WADA-banned at all times.
A clinical monograph on FGL (FGLL) — the NCAM-derived FGFR1 agonist peptide marketed for memory and neuroprotection. Deep rodent data, one single-dose human safety study, and zero efficacy proof in people.
A clinical monograph on Cortagen (Ala-Glu-Asp-Pro) — the Khavinson-program 'cytogen' tetrapeptide marketed for nerve repair and neuroprotection. One intriguing rat nerve-regeneration signal, no human RCTs, and an unapproved-research-chemical legal status.
A clinical monograph on Chonluten — the Russian "Khavinson" bronchial bioregulator sold as the tripeptide Glu-Asp-Gly (EDG). Single-lab in-vitro data on a related peptide, no human RCT, and an unapproved 2026 legal status.
A clinical monograph on Bronchogen — the lung/bronchial 'bioregulator' tetrapeptide (ADEL/AEDL) from the Khavinson short-peptide program. Promising preclinical biology, zero human efficacy or safety trials, and an unapproved 2026 legal status.
A clinical monograph on adipotide (FTPP) — the fat-targeted proapoptotic peptide that shrinks white fat by ablating its blood supply. Dramatic preclinical fat loss, no completed human trial, and a documented kidney-toxicity signal.
Research Chemical is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Research Chemical, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.